SeekingAlpha · Mar 5, 2026
CR
NASDAQ · CRMD
CorMedix Inc.
Healthcare · Biotechnology
$8.23
Down-$0.03 (-0.36%)
Updated Aug 21, 2026, 11:14 PM
SID Score
6.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 924.2M
- P/E ratio
- 5.48
- Dividend yield
- 0.00%
- 52-week range
- $6.14 – $9.09
- Volume
- 1M
- Avg. volume
- 2.73M
Price performance
CRMD price history
1M range · 21 trading sessions · Daily adjusted prices
CRMD closed at $8.23 after 21 trading sessions, up 2.24% for the selected period.
- Last close
- $8.23
- Period change
- +2.24%
- Period low
- $7.10
- Period high
- $8.52
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 20, 2026 | $8.49 | $8.5449 | $8.19 | $8.23 | 1M |
| Aug 19, 2026 | $8.30 | $8.53 | $8.11 | $8.52 | 1.47M |
| Aug 18, 2026 | $7.71 | $8.27 | $7.71 | $8.17 | 2.03M |
| Aug 17, 2026 | $7.55 | $8.11 | $7.4801 | $7.67 | 2.17M |
| Aug 14, 2026 | $8.05 | $8.198 | $7.46 | $7.54 | 2.7M |
| Aug 13, 2026 | $8.39 | $8.98 | $7.76 | $8.14 | 6.07M |
| Aug 12, 2026 | $7.30 | $7.31 | $7.10 | $7.10 | 1.35M |
| Aug 11, 2026 | $7.60 | $7.62 | $7.25 | $7.30 | 1.18M |
| Aug 10, 2026 | $7.40 | $7.55 | $7.31 | $7.53 | 842.65K |
| Aug 7, 2026 | $7.58 | $7.585 | $7.395 | $7.44 | 740.97K |
| Aug 6, 2026 | $7.43 | $7.52 | $7.38 | $7.51 | 702.37K |
| Aug 5, 2026 | $7.52 | $7.57 | $7.37 | $7.41 | 615.54K |
| Aug 4, 2026 | $7.60 | $7.66 | $7.48 | $7.52 | 651.74K |
| Aug 3, 2026 | $7.60 | $7.635 | $7.40 | $7.55 | 856.1K |
| Jul 31, 2026 | $7.49 | $7.55 | $7.30 | $7.53 | 637.87K |
| Jul 30, 2026 | $7.28 | $7.585 | $7.23 | $7.49 | 1.18M |
| Jul 29, 2026 | $7.36 | $7.4325 | $7.13 | $7.19 | 1.36M |
| Jul 28, 2026 | $7.60 | $7.69 | $7.27 | $7.35 | 1.25M |
| Jul 27, 2026 | $8.00 | $8.12 | $7.58 | $7.60 | 1.18M |
| Jul 24, 2026 | $8.07 | $8.085 | $7.83 | $7.87 | 625.29K |
| Jul 23, 2026 | $7.85 | $8.0725 | $7.76 | $8.05 | 698.51K |
Latest CRMD news
The latest Smart Investors Daily articles mentioning CRMD.
Stock researchCompany · Overview
CRMD research
Overview
Company profile and research snapshot.
Company profile
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $19.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | RBC Capital | Outperform | — |
| Jul 7, 2026 | RBC Capital | Outperform | — |
| Apr 28, 2026 | RBC Capital | Outperform | — |
| Apr 28, 2026 | Leerink Partners | Outperform | — |
| Apr 28, 2026 | Citizens | Market Outperform | — |
News briefing
No generated briefing is available yet.
ChartMill · Mar 5, 2026
CorMedix Inc (NASDAQ:CRMD) Shares Drop on Q4 2025 Earnings Miss
CorMedix reports strong Q4 2025 revenue growth but misses EPS estimates, leading to a sharp pre-market stock decline.
Benzinga · Mar 5, 2026
CorMedix shares are trading lower after the company reported mixed Q4 financial results.
Benzinga · Mar 5, 2026
CORRECTION: Cormedix Affirms FY2026 Sales Guidance of $300.000M-$320.000M
Cormedix (NASDAQ:CRMD) affirms FY2026 sales outlook from $300.000 million-$320.000 million to $300.000 million-$320.000 million.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
